Bob Löwenberg - Selected Publications#

Web-of-Science: Number of cited publications: 940, total citations 48179. avergae citation per item 50,93, - h-index 100

B.Löwenberg, W.van Putten, M.Theobald, G.Gmüt, L.Verdonck, P.Sonneveld, M.Fey, H.Schouten, G.de Greef, A.Ferrant, T.Kovacsovics, A.Gratwohl, S.Daenen, P.Huijgens, M.Boogaerts for the Dutch-Belgian Hemato-Oncology Cooperative Group HOVON and the Swiss Group for Clinical Cancer Research - Effect of priming with granulocyte-colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
New Engl.J.Med. 2003, 349, 743-752. [ IF 91.253]

P.J.M.Valk, R.G.W.Verhaak, M.A.Beijen, C.A.J.Erpelinck, S.Barjesteh van Waalwijk van Doorn-Khosrovani, J.M.Boer, H.B.Beverloo, M.J.Moorhouse, P.J.van der Spek, B.Löwenberg, R.Delwel – Prognostic useful gene-expression profiles in acute myeloid leukema.
New Engl.J.Med. 2004, 350, 1617-1628. [ IF 91.253]

B. Löwenberg, T. Pabst, E. Vellenga, W. van Putten, H.C. Schouten, C. Graux, A. Ferrant, P. Sonneveld, B.J. Biemond, A. Gratwohl, G.E. de Greef, L.F. Verdonck, M.R. Schaafsma, M. Gregor, M. Theobald, U. Schanz, J. Maertens, G.J. Ossenkoppele, Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group – Cytarabine dose for acute myeloid leukemia.
N Engl J Med, 2011 Mar 17; 364 (11): 1027-36. [ IF 91.253]

H. Döhner, E. Estey, D. Grimwade, S. Amadori, F.R. Appelbaum, T. Büchner, H. Dombret, B.L. Ebert, P. Fenaux, R.A. Larson, R.L. Levine, F. Lo-Coco, T. Naoe, D. Niederwieser, G.J. Ossenkoppele, M. Sanz, J. Sierra, M.S. Tallman, H.F. Tien, A.H. Wei, B. Löwenberg, C.D. Bloomfield - Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Blood, 2017 Jan 26;129(4):424-447. [ IF 23.6]

M. Jongen-Lavrencic, T. Grob, D. Hanekamp, F.G. Kavelaars, A. Al Hinai, A. Zeilemaker, C.A.J. Erpelinck-Verschueren, P.L. Gradowska, R. Meijer, J. Cloos, B.J. Biemond, C. Graux, M. van Marwijk Kooy, M.G. Manz, T. Pabst, J.R. Passweg, V. Havelange, G.J. Ossenkoppele, M.A. Sanders, G.J. Schuurhuis, B. Löwenberg, P.J.M. Valk. - Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
N Engl J Med., 2018 Mar 29;378(13):1189-1199. [ IF 91.253]

E.M. Stein, G. Garcia-Manero, D.A. Rizzieri, R. Tibes, J.G. Berdeja, M.R. Savona, M. Jongen-Lavrenic, J.K. Altman, B. Thomson, S.J. Blakemore, S.R. Daigle, N.J. Waters, A.B. Suttle, A. Clawson, R. Pollock, A. Krivtsov, S.A. Armstrong, J. DiMartino, E. Hedrick, B. Löwenberg, M.S. Tallman - The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Blood. 2018 Jun 14;131(24):2661-2669. [ IF 23.6]

C.A. Uyl-de Groot, B. Löwenberg - Sustainability and affordability of cancer drugs: a novel pricing model.
Nat Rev Clin Oncol. 2018 Jul;15(7):405-406. [ IF 77.6]

G. Huls, D.A. Chitu, V. Havelange, M. Jongen-Lavrencic, A.A. van de Loosdrecht, B.J. Biemond, H. Sinnige, B. Hodossy, C. Graux, R. van Marwijk Kooy, O. de Weerdt, D. Breems, S. Klein, J. Kuball, D. Deeren, W. Terpstra, M.C. Vekemans, G.J. Ossenkoppele, E. Vellenga, B. Löwenberg - Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Blood. 2019 Mar 28;133(13):1457-1464. - [ IF 23.6]

H. Döhner, A.H. Wei, B. Löwenberg - Towards precision medicine for AML.
Nat Rev Clin Oncol. 2021 Sep;18(9):577-590. [ IF 77.6]